ATE368116T1 - Schutzantigen des epstein-barr-virus - Google Patents

Schutzantigen des epstein-barr-virus

Info

Publication number
ATE368116T1
ATE368116T1 AT00954003T AT00954003T ATE368116T1 AT E368116 T1 ATE368116 T1 AT E368116T1 AT 00954003 T AT00954003 T AT 00954003T AT 00954003 T AT00954003 T AT 00954003T AT E368116 T1 ATE368116 T1 AT E368116T1
Authority
AT
Austria
Prior art keywords
ebna
barr virus
epstein
protective antigens
vaccine
Prior art date
Application number
AT00954003T
Other languages
English (en)
Inventor
Ralph Steinman
Christian Muenz
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE368116T1 publication Critical patent/ATE368116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00954003T 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus ATE368116T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14897199P 1999-08-13 1999-08-13

Publications (1)

Publication Number Publication Date
ATE368116T1 true ATE368116T1 (de) 2007-08-15

Family

ID=22528253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954003T ATE368116T1 (de) 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus

Country Status (7)

Country Link
EP (1) EP1200594B1 (de)
JP (1) JP2004500335A (de)
AT (1) ATE368116T1 (de)
AU (1) AU775760B2 (de)
CA (1) CA2380991A1 (de)
DE (1) DE60035695T2 (de)
WO (1) WO2001012215A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474497C (en) * 2002-01-30 2013-12-03 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
AU2003236508A1 (en) * 2002-06-14 2003-12-31 Mayo Foundation For Medical Education And Research Epstein-barr virus-specific immunization
US8329660B2 (en) * 2003-10-03 2012-12-11 The Brigham And Women's Hospital, Inc. Tim-3 ligands and methods thereof
JP4956427B2 (ja) * 2004-07-21 2012-06-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
EP1948232A4 (de) * 2005-11-18 2010-09-22 Univ Ohio State Res Found Virale genprodukte und verfahren zur schutzimpfung vor viruserkrankungen
JP2015516376A (ja) * 2012-03-19 2015-06-11 ドイチェス クレブスフォルシュンクスツェントルム Ｔ細胞エピトープを含む、ｂ細胞受容体複合体結合タンパク質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002563A1 (en) * 1994-07-13 1996-02-01 Cornell Research Foundation, Inc. Epstein-barr virus nuclear antigen 1 protein and its expression and recovery
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells

Also Published As

Publication number Publication date
EP1200594B1 (de) 2007-07-25
DE60035695T2 (de) 2008-04-10
AU775760B2 (en) 2004-08-12
EP1200594A2 (de) 2002-05-02
JP2004500335A (ja) 2004-01-08
DE60035695D1 (de) 2007-09-06
CA2380991A1 (en) 2001-02-22
WO2001012215A3 (en) 2001-08-23
AU6636200A (en) 2001-03-13
WO2001012215A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
Khanna et al. Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
Cohen Vaccine development for Epstein-Barr virus
Rickinson et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
Münz et al. Immune escape by Epstein–Barr virus associated malignancies
Leen et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
Bourgault et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
Khanna et al. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
MY142842A (en) Vaccine against hpv
NZ505322A (en) Protein expression in baculovirus vector expression systems using low multiplicity of infection
EE9800105A (et) Dendriitrakke stimuleeriv faktor
TR200200838T2 (tr) İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
MXPA02002483A (es) Vacuna contra vhb y vph.
Rooney et al. Treatment of relapsed Hodgkin’s disease using EBV-specific cytotoxic T cells
ATE368116T1 (de) Schutzantigen des epstein-barr-virus
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
Lee Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy
Khanna et al. Immunotherapeutic strategies for EBV-associated malignancies
DK0882132T3 (da) Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
Chen et al. T cell epitope screening of Epstein-Barr virus fusion protein gB
PT1171587E (pt) Peptido derivado do antigenio muc-1 para desencadear uma reaccao imunitaria contra celulas tumorais

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties